Thornberry Nancy 4

What Happened Nancy Thornberry, a director of Vertex Pharmaceuticals (VRTX), received equity awards on May 1, 2026. The filing shows 1,433 shares acquired on vesting of RSUs (derivative, fully vested), a new grant of 472 restricted stock units (RSUs) that vest on the first anniversary of the grant, and a disposition of 398 shares to the issuer in exchange for 398 deferred stock units under Vertex’s deferred compensation plan. All awards show a $0.00 per-share acquisition price (typical for RSUs).

Key Details

• Transaction date: 2026-05-01; Form 4 filed 2026-05-05 (timely).
• Grants/acquisitions:
  • 1,433 shares (derivative) acquired on vesting; footnote indicates fully vested (F3).
  • 472 RSUs granted that vest on the first anniversary of the grant (F1).
• Disposition/deferment:
  • 398 shares reported as disposed to the issuer in exchange for 398 deferred stock units (F2). Those deferred stock units each represent one share and will be paid in stock on certain events (termination, change of control, disability or death) (F4).
• Prices/values: all acquisitions reported at $0.00 per share (no cash paid); the disposition was an in-kind exchange (not a market sale).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• These transactions consist of RSU vesting, a new RSU grant, and a deferral into deferred stock units — not open-market buying or selling. RSU grants and deferrals are common compensation actions and do not by themselves indicate a buying or selling decision in the market.
• Deferred stock units are treated as a form of delayed compensation and convert to common shares only upon the specified payout events.